Skip to content
Search

Latest Stories

Submit Guest Post

Indian pharmacist dies after drinking botched coronavirus treatment

An Indian pharmacist died and his boss was left hospitalised after the pair drank a chemical concoction they had developed in an effort to treat coronavirus, police said Saturday.

The men worked for a herbal medicine company and were testing their treatment -- a mix of nitric oxide and sodium nitrate -- at a home in southern Chennai city.


K Sivanesan, 47, died on the spot, said local police chief Ashok Kumar.

His colleague Rajkumar was recovering from the poisoning.

Kumar said Sivanesan bought the chemicals from a local market and developed the formula after conducting research on the internet.

There are no approved medicines or vaccines for treating COVID-19, triggering a global race for a new drug for the disease that has killed nearly 300,000 people.

Nearly 60,000 cases have been detected in India, which has imposed a drastic nationwide lockdown in an effort to halt the spread of the disease.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Shein sales dip

Shein says rising trade barriers are making its low-cost retail model harder to sustain

Shein

The rule change that's forcing Shein to rethink its low-price strategy

  • Shein reported a £74 million ($99 million) quarterly loss after US tariff changes hit sales.
  • The retailer says it may raise prices to offset higher import costs in key markets.
  • Fresh EU import charges could add further pressure to Shein's low-cost business model.

Shein's low-cost fashion business is facing one of its biggest tests yet after new trade rules in the US hit sales and raised questions over whether the retailer can continue offering ultra-cheap products in its biggest markets.

In a regulatory filing ahead of its planned Hong Kong stock market listing, the fast-fashion company reported a net loss of $99 million (£74 million) for the three months to the end of March, compared with a $395 million (£296 million) profit a year earlier. Revenue rose just 1.1 per cent to $9.05 billion (£6.78 billion), signalling a sharp slowdown in growth.

Keep ReadingShow less